News

Cediranib Falls Short in Phase III Glioblastoma Trial

Publish date: November 23, 2010

 

FROM THE ANNUAL MEETING OF THE SOCIETY FOR NEURO-ONCOLOGY

Dr. Batchelor has received research funding and honoraria from AstraZeneca, which sponsored the trial and is developing cediranib.

Pages

Recommended Reading

FDA and CDC to Consider Gardasil for Anal Cancer Prevention
MDedge Internal Medicine
One-Third of Medicare Patients With Cancer Die in Hospitals
MDedge Internal Medicine
OncoMap Gene Sequencing Finds 50 Mutations in Ovarian Tumors
MDedge Internal Medicine
Link Between Physical Illness and PTSD Remains Underrecognized
MDedge Internal Medicine
Can Bundled Cancer-Care Payments Save a Bundle?
MDedge Internal Medicine
FDA Committee Considers Gardasil for Anal Cancer Prevention
MDedge Internal Medicine
FDA Panel Divided on Melanoma Diagnosis Aid
MDedge Internal Medicine
FDA Approves Denosumab for Bone Metastases
MDedge Internal Medicine
Wide Screening for Lynch Syndrome Seen as Cost Effective
MDedge Internal Medicine
Patients Lukewarm on Cosmetic Outcomes After Breast-Conserving Surgery
MDedge Internal Medicine